JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

/PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative biotechnology company focusing on developing, manufacturing and commercializing...

Related Keywords

Hong Kong ,Jian Zhou ,Zhejiang ,China ,Taiwan ,Yang Xie ,Shanghai ,Macao ,Macau General ,Macau ,Chinese ,Qiang Gao ,Jia Fan ,Association Of Southeast Asian Nations ,Southeast Asian ,Zheng Gang Ren ,Chimeric Antigen ,Cell Therapy ,Advanced Hepatocellular Carcinoma ,Clin Cancer Res ,Jw Therapeutics ,